BRPI0511118A - polipeptìdeos de haemophilus influenzae não transcritos - Google Patents

polipeptìdeos de haemophilus influenzae não transcritos

Info

Publication number
BRPI0511118A
BRPI0511118A BRPI0511118-8A BRPI0511118A BRPI0511118A BR PI0511118 A BRPI0511118 A BR PI0511118A BR PI0511118 A BRPI0511118 A BR PI0511118A BR PI0511118 A BRPI0511118 A BR PI0511118A
Authority
BR
Brazil
Prior art keywords
polypeptides
haemophilus influenzae
untranscribed
nthi
influenzae
Prior art date
Application number
BRPI0511118-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Vega Masignani
Maria Arico
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BRPI0511118A publication Critical patent/BRPI0511118A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0511118-8A 2004-05-14 2005-05-16 polipeptìdeos de haemophilus influenzae não transcritos BRPI0511118A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410866.8A GB0410866D0 (en) 2004-05-14 2004-05-14 Haemophilius influenzae
PCT/IB2005/001775 WO2005111066A2 (en) 2004-05-14 2005-05-16 Polypeptides from non-typeable haemophilus influenzae

Publications (1)

Publication Number Publication Date
BRPI0511118A true BRPI0511118A (pt) 2007-11-27

Family

ID=32527109

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511118-8A BRPI0511118A (pt) 2004-05-14 2005-05-16 polipeptìdeos de haemophilus influenzae não transcritos

Country Status (10)

Country Link
US (4) US7749518B2 (enExample)
EP (5) EP2343313A1 (enExample)
JP (2) JP2008506364A (enExample)
CN (1) CN1997663A (enExample)
BR (1) BRPI0511118A (enExample)
CA (1) CA2566632A1 (enExample)
GB (1) GB0410866D0 (enExample)
IN (1) IN2015KN00290A (enExample)
RU (1) RU2432357C2 (enExample)
WO (1) WO2005111066A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1790660E (pt) * 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
SI2353608T1 (sl) * 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CA2602665A1 (en) * 2005-03-30 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Haemophilus influenzae type b
JP2008546390A (ja) 2005-06-16 2008-12-25 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド 分類不能型インフルエンザ菌の中耳炎単離物の遺伝子
AU2006277076B2 (en) 2005-08-10 2012-03-29 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CA2636566C (en) 2006-01-17 2018-03-13 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
US9132183B2 (en) * 2007-03-09 2015-09-15 Newport Laboratories Modified live (JMSO strain) Haemophilus parasuis vaccine
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
NZ593674A (en) * 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
WO2010092176A2 (en) * 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
HRP20161352T1 (hr) 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
DK4226941T3 (da) 2010-08-31 2024-12-02 Glaxosmithkline Biologicals Sa Pegylerede liposomer til levering af immunogen-kodende rna
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
CA2835510A1 (en) * 2011-05-11 2012-11-15 Riesbeck Healthcare Sweden Ab Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
CN103764121A (zh) 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
US10279026B2 (en) * 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN108671228A (zh) * 2012-04-26 2018-10-19 诺华股份有限公司 抗原和抗原组合
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
EA201891018A1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
US10502027B2 (en) * 2014-08-27 2019-12-10 Switchfloat Holdings Limited Oil field tubular and an internal sleeve for use therewith, and a method of deactivating a float valve within the oil field tubular
EP3188760B1 (en) 2014-09-05 2023-12-06 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3307307A4 (en) 2015-06-09 2019-05-01 The Board of Regents of the University of Oklahoma COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
EP3322408B1 (en) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
WO2017185250A1 (zh) * 2016-04-27 2017-11-02 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2018206552C1 (en) 2017-01-04 2025-04-10 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
EP3565834B1 (en) 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US20180221468A1 (en) * 2017-01-19 2018-08-09 Iowa State University Research Foundation, Inc. Haemophilus influenzae immunogen
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
MX2021003838A (es) 2018-10-05 2021-05-27 Res Inst Nationwide Childrens Hospital Derivados de proteina hmgb1 para la eliminacion de biopeliculas.
WO2020174044A1 (en) * 2019-02-27 2020-09-03 Evaxion Biotech Aps Vaccines targeting h. influenzae
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
WO2021174092A1 (en) * 2020-02-28 2021-09-02 Trait Biosciences, Inc. Novel systems, methods, and compositions for the glycosylation of cannabinoid compounds
US12116614B2 (en) 2020-06-30 2024-10-15 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity
AU2021360494A1 (en) 2020-10-14 2023-05-18 George Mason Research Foundation, Inc. Ionizable lipids and methods of manufacture and use thereof
CN115678869B (zh) * 2021-07-28 2025-08-29 梅花(上海)生物科技有限公司 一株重组菌株及其生产氨基酸的方法
EP4387596A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Low-dose lyophilized rna vaccines and methods for preparing and using the same
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
CN114574456B (zh) * 2022-03-18 2022-08-12 华南理工大学 一种亚硝酸盐还原酶突变体及其编码基因和应用
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
CN116236575B (zh) * 2023-03-07 2025-03-25 北京化工大学 一种光控偶联型纳米探针及其制备方法、光控偶联的纳米颗粒组合物与应用
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
CN118388664B (zh) * 2024-05-21 2024-12-03 广东省农业科学院动物卫生研究所 副猪嗜血杆菌融合抗原及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB234768A (en) * 1924-05-28 1925-08-27 Ritter Dental Mfg Company Inc Improvements in adjustable brackets for supporting head-rests or other articles
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
BR9408006A (pt) * 1993-11-08 1996-12-03 Connaught Lab Molécula de ácido nucléico isolada e purificada vetor e vetor de express o adaptados para transformaçao de hospedeiro hospedeiro transformado proteina receptora "transferrin" recombinante ou fragmento ou análogo da mesma proteina Tbpl purificada e isolada proteina Tbp2 purificada e isolada peptídeo composiç o imunogênica vetor ativo para fornecimento de proteina receptora "transferrin" vetor de plasmideo linhagem de haemophilus processo para produzir proteina Tbp2 ou Tbpl purificada e isolada
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CA2320223A1 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
WO2000056359A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
DK2270171T5 (da) 2000-10-02 2013-11-18 Id Biomedical Corp Quebec Haemophilus influenzae-antigener og tilsvarende DNA-fragmenter
GB0026002D0 (en) * 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
GB0109289D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Novel compounds
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0200025D0 (en) * 2002-01-02 2002-02-13 Glaxosmithkline Biolog Sa Novel compounds
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
WO2004078949A2 (en) * 2003-03-06 2004-09-16 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP2008546390A (ja) 2005-06-16 2008-12-25 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド 分類不能型インフルエンザ菌の中耳炎単離物の遺伝子
CA2636566C (en) 2006-01-17 2018-03-13 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
AT507928B1 (de) 2008-06-30 2015-09-15 Coil Holding Gmbh Drosselspule für elektrische energieversorgungsnetze mit reduzierten schallemissionen
WO2011106661A1 (en) 2010-02-25 2011-09-01 B/E Aerospace, Inc. Calibration method for led lighting systems

Also Published As

Publication number Publication date
US20100303822A1 (en) 2010-12-02
WO2005111066A3 (en) 2006-05-26
IN2015KN00290A (enExample) 2015-06-12
JP2008506364A (ja) 2008-03-06
US9102729B2 (en) 2015-08-11
US20140234363A1 (en) 2014-08-21
JP2012000112A (ja) 2012-01-05
CN1997663A (zh) 2007-07-11
US20080267966A1 (en) 2008-10-30
US20120148615A1 (en) 2012-06-14
US7749518B2 (en) 2010-07-06
US8124098B2 (en) 2012-02-28
RU2432357C2 (ru) 2011-10-27
WO2005111066A8 (en) 2007-05-18
EP2343313A1 (en) 2011-07-13
EP2351773A1 (en) 2011-08-03
CA2566632A1 (en) 2005-11-24
GB0410866D0 (en) 2004-06-16
EP2341069A1 (en) 2011-07-06
EP1745067A2 (en) 2007-01-24
RU2006144093A (ru) 2008-06-20
EP2351774A1 (en) 2011-08-03
WO2005111066A2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
BRPI0507026A (pt) proteìnas de fusão de albumina
NZ591415A (en) Haemophilus influenzae type B
MX2008001865A (es) Proteinas de fusion de albumina.
MX2009002816A (es) Proteinas de fusion de albumina.
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
NZ543467A (en) The severe acute respiratory syndrome coronavirus
BR9907691A (pt) Derivados de antìgeno associado a tumor da famìlia mage, e sequências de ácido nucléico codificando os mesmos, usados para a preparação de proteìnas de fusão e de composições para vacinação
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
WO2001079443A3 (en) Albumin fusion proteins
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
WO2003060071A3 (en) Albumin fusion proteins
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
BR0007840A (pt) Proteìnas de fusão her-2/neu
JP2004504001A (ja) スプライソソーム媒介ｒｎａトランスースプライシングにおける使用のための方法及び組成物
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
ATE522541T1 (de) Bakterielle adhäsine konformere
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
DE3856240D1 (de) Herstellung der p1 proteine und impfstoffe gegen gonorrhöe
DK0771352T3 (da) Ikke-typebestemmelig Haemophilus influenzae-LKP-spids-adhesinprotein og nukleinsyre
NO20081541L (no) Ny sjo-lus vaksine
TW200724679A (en) Treatment of disease using an improved regulated expression system
ATE278011T1 (de) Human dnase ii
BR0308180A (pt) protéinas de superfìcie de leptospira
ATE512981T1 (de) Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements